Clinical Trials Logo

Filter by:
NCT ID: NCT04618393 Terminated - Clinical trials for Advanced Solid Tumors

A Study of EMB-02 in Participants With Advanced Solid Tumors

Start date: March 11, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The primary purpose of this study is to identify the recommended Phase 2 dose(s) (RP2Ds) and schedule assessed to be safe for EMB-02 and to characterize the safety and tolerability of EMB-02 at the RP2Ds. Pharmacokinetics (PK), immunogenicity, and the anti-tumor activity of EMB-02 will also be assessed.

NCT ID: NCT04614246 Terminated - Endometriosis Clinical Trials

Study to Gather Information How Well Three Different Doses of BAY1817080 Given Twice Daily Over 12 Weeks Work in Comparison to an Inactive Pill (Placebo) and Elagolix in Women Suffering From Pain Related to a Condition Where the Tissue That Usually Grows Inside the Womb Grows Outside of the Womb

SCHUMANN
Start date: January 29, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess safety and efficacy of BAY 1817080 compared to elagolix and placebo in women with symptomatic endometriosis. Study details include: - Study duration: 155 up to 285 days - Treatment duration: 84 days - Visit frequency: 3 laboratory every 2 weeks for participants on BAY 1817080 or placebo

NCT ID: NCT04612790 Terminated - Bullous Pemphigoid Clinical Trials

A Study to Investigate the Use of Benralizumab in Patients With Bullous Pemphigoid.

FJORD
Start date: March 31, 2021
Phase: Phase 3
Study type: Interventional

The purpose of this study is to investigate the use of benralizumab is effective in the treatment of patients symptomatic Bullous Pemphigoid (BP).

NCT ID: NCT04611321 Terminated - Clinical trials for Advanced Cutaneous Squamous Cell Carcinoma

Study of IBI318 in Patients With Advanced Cutaneous Squamous Cell Carcinoma

Start date: December 1, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of IBI318 (anti-PD-1/PD-L1) in adult participants with metastatic (nodal or distant) cutaneous squamous cell carcinoma (CSCC), or unresectable locally advanced CSCC that is not amenable to surgery and/or radiation.

NCT ID: NCT04609397 Terminated - Behçet Disease Clinical Trials

A Study to Evaluate the Efficacy and Safety of Hemay005 in the Treatment of Behçet Disease

Start date: November 30, 2020
Phase: Phase 2
Study type: Interventional

This is a phase 2, multi-center, randomized, placebo-controlled, double-blind, parallel-group study with an equal randomization among the Hemay005 high dose, lower dose and placebo treatment groups. After subject randomization, each subject will enter an core-treatment Phase for 12 weeks following an extended-treatment phase for another 12weeks and a follow up phase for 4weeks.

NCT ID: NCT04607668 Terminated - Clinical trials for Colorectal Cancer Metastatic

Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC):

PRESERVE1
Start date: October 16, 2020
Phase: Phase 3
Study type: Interventional

This is a randomized, double-blind, placebo-controlled, global, multicenter, Phase 3 trial evaluating the impact of trilaciclib on myelopreservation and anti-tumor efficacy when administered prior to FOLFOXIRI/bevacizumab in patients with pMMR/MSS mCRC who have not received systemic therapy for metastatic disease.

NCT ID: NCT04607252 Terminated - Clinical trials for Atypical Endometrial Hyperplasia

Metformin Plus Megestrol Acetate as a Fertility-sparing Treatment in Patients With Atypical Endometrial Hyperplasia

Start date: January 11, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

To verify whether metformin could improve the effect of progestin as fertility-sparing treatment in patients with atypical endometrial hyperplasia(AEH).

NCT ID: NCT04602065 Terminated - Clinical trials for Extranodal NK/T Cell Lymphoma, Nasal Type

Evaluation of Safety and Efficacy of IBI318 Monotherapy for Relapsed/Refractory Extranodal NK/T Cell Lymphoma (Nasal Type) Trial

Start date: November 24, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of IBI318 monotherapy for relapsed/refractory extranodal NK/T cell lymphoma (nasal type).

NCT ID: NCT04601610 Terminated - Advanced HCC Clinical Trials

KN046 Combined With Ningatinib in the Treatment of Advanced Hepatocellular Carcinoma

Start date: June 7, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This study is an open, multi-center clinical trial, the purpose is to study the safety and preliminary efficacy of KN046 combined with Ningatinib in subjects with advanced hepatocellular carcinoma.

NCT ID: NCT04601285 Terminated - Clinical trials for Advanced Solid Tumors

A Phase I Study of JS108 in Patients With Advanced Solid Tumors

Start date: October 28, 2020
Phase: Phase 1
Study type: Interventional

This is a phase I, open-label, first-in-human clinical study designed to evaluate the safety, tolerability, PK profile and efficacy of JS108 for patients with advanced solid tumors. This study is divided into 3 periods: dose escalation period, dose expansion period, and clinical expansion period.